Categories: HospitalsNews

Harrington Discovery Institute Opens Call for 2026 Harrington Scholar-Innovator Award

Unique program for physician-scientists to advance promising discoveries into medicines

CLEVELAND, April 16, 2025 /PRNewswire/ — Harrington Discovery Institute at University Hospitals is now accepting Letters of Intent for the 2026 Harrington Scholar-Innovator Award for physician-scientists. The award offers successful applicants multiple opportunities for funding in addition to expertise from pharma-experienced leaders with a track record of bringing drugs to market. Intellectual property rights are retained by the award recipient and/or their institution. Up to 12 Scholar-Innovators will be selected to receive:

  • $100,000 guaranteed grant award;
  • Drug and business development support from Harrington’s Therapeutics Development Center advisors;  
  • Opportunity to compete for acceleration funds up to $300,000;
  • Opportunity to qualify for investment funds typically up to $2M.

The call is open to physician-scientists at accredited academic medical centers, research institutions and universities in the United States and Canada. Applicants must have a doctorate in medicine. Selection criteria include innovation, creativity and the potential for clinical impact. Award recipients will be selected by Harrington Discovery Institute’s Scientific Advisory Board and announced in April 2026.

The deadline to submit a brief Letter of Intent is June 4, 2025. The full application deadline, for those invited to submit, is August 4, 2025.

Learn more and apply to the 2026 Scholar-Innovator Award:
HarringtonDiscovery.org/Scholar-Innovators

View original content:https://www.prnewswire.com/news-releases/harrington-discovery-institute-opens-call-for-2026-harrington-scholar-innovator-award-302429952.html

SOURCE Harrington Discovery Institute

Staff

Recent Posts

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

47 minutes ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

15 hours ago

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

18 hours ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

18 hours ago

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…

18 hours ago